TitleAssociate Professor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024 Apr 11; 15(1):3152. PMID: 38605064; PMCID: PMC11009351.
    2. Li H, Hu X, Ning MS, Fuller GN, Stewart JM, Gilliam JC, Wu J, Le X, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Futreal A, Zhang J. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Front Oncol. 2024; 14:1324057. PMID: 38590653; PMCID: PMC10999639.
    3. Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463. PMID: 38471502; PMCID: PMC10983039.
      Citations:    Fields:    Translation:Humans
    4. Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, Vaporciyan A, Gibbons DL, Heymach JV, Lee JJ, Woodman SE, Chung C, Jaffray DA, Altan M, Lou Y, Zhang J. Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers (Basel). 2024 Feb 26; 16(5). PMID: 38473297; PMCID: PMC10931294.
    5. Wang Z, Fang Y, Liu Z, Hao N, Zhang HH, Sun X, Que J, Ding H. Adapting Nanopore Sequencing Basecalling Models for Modification Detection via Incremental Learning and Anomaly Detection. bioRxiv. 2023 Dec 20. PMID: 38187611; PMCID: PMC10769248.
    6. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets. JTO Clin Res Rep. 2024 Feb; 5(2):100623. PMID: 38357092; PMCID: PMC10864847.
    7. Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Trevi?o S, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res. 2023 12 01; 29(23):4958-4972. PMID: 37733794; PMCID: PMC10690143.
      Citations:    Fields:    Translation:Humans
    8. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506. PMID: 38012986.
      Citations:    Fields:    Translation:Humans
    9. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist. 2023 Nov 02; 28(11):e1065-e1074. PMID: 37156009; PMCID: PMC10628566.
      Citations: 1     Fields:    
    10. Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 11 01; 29(21):4408-4418. PMID: 37432985; PMCID: PMC10618656.
      Citations: 1     Fields:    Translation:Humans
    11. Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4. PMID: 37816395.
      Citations:    Fields:    Translation:Humans
    12. Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel). 2023 Oct 01; 15(19). PMID: 37835518; PMCID: PMC10571722.
    13. Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, Velcheti V, Sterman DH, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol. 2023 Dec; 36(12):100326. PMID: 37678674; PMCID: PMC10841057.
      Citations: 1     Fields:    Translation:Humans
    14. Konen JM, Rodriguez BL, Wu H, Fradette JJ, Gibson L, Diao L, Wang J, Schmidt S, Wistuba II, Zhang J, Gibbons DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. J Clin Invest. 2023 09 01; 133(17). PMID: 37655662; PMCID: PMC10471170.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    15. Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, Wang CM, Chen CL, Mitsuya K, Osmulski PA, Gaczynska ME, Kirma NB, Vadlamudi RK, Gibbons DL, Warner S, Brenner AJ, Mahadevan D, Michalek JE, Huang TH, Taverna JA. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep. 2023 09 26; 42(9):113067. PMID: 37659081; PMCID: PMC10577802.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    16. Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, Grand Challenge PRECISION Consortium, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell. 2023 08 31; 186(18):3968-3982.e15. PMID: 37586362.
      Citations: 2     Fields:    Translation:HumansCells
    17. Perez-Oquendo M, Manshouri R, Tian Y, Fradette JJ, Rodriguez BL, Kundu ST, Gibbons DL. ZEB1 Is Regulated by K811 Acetylation to Promote Stability, NuRD Complex Interactions, EMT, and NSCLC Metastasis. Mol Cancer Res. 2023 08 01; 21(8):779-794. PMID: 37255406; PMCID: PMC10390859.
      Citations:    Fields:    
    18. Reyes-Castro RA, Chen SY, Seemann J, Kundu ST, Gibbons DL, Arur S. Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas. Sci Adv. 2023 07 28; 9(30):eadf6210. PMID: 37494452; PMCID: PMC10371025.
      Citations:    Fields:    Translation:HumansAnimalsCells
    19. Qureshi S, Arani N, Parvathareddy V, Tchakarov A, Abdelrahim M, Suarez-Almazor M, Zhang J, Gibbons DL, Heymach J, Altan M, Abudayyeh A. Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. Front Nephrol. 2023; 3:1168614. PMID: 37675380; PMCID: PMC10479603.
    20. Aldea M, Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. PMID: 37068173.
      Citations: 3     Fields:    Translation:Humans
    21. Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A. 2023 07 11; 120(28):e2220276120. PMID: 37406091; PMCID: PMC10334751.
      Citations:    Fields:    Translation:HumansCells
    22. Rodriguez BL, Chen L, Li Y, Miao S, Peng DH, Fradette JJ, Diao L, Konen JM, Alvarez FRR, Solis LM, Yi X, Padhye A, Gibson LA, Ochieng JK, Zhou X, Wang J, Gibbons DL. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol. 2023; 14:1161869. PMID: 37449205; PMCID: PMC10336223.
      Citations:    Fields:    Translation:HumansCells
    23. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep. 2023 Aug; 4(8):100533. PMID: 37649681; PMCID: PMC10462815.
      Citations: 1     
    24. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health. 2023 Jul; 5(7):e404-e420. PMID: 37268451; PMCID: PMC10330920.
      Citations:    Fields:    Translation:Humans
    25. Parra ER, Zhang J, Jiang M, Tamegnon A, Pandurengan RK, Behrens C, Solis L, Haymaker C, Heymach JV, Moran C, Lee JJ, Gibbons D, Wistuba II. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nat Commun. 2023 04 25; 14(1):2364. PMID: 37185575; PMCID: PMC10130161.
      Citations:    Fields:    Translation:HumansCells
    26. Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, J?nne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023 05; 55(5):807-819. PMID: 37024582; PMCID: PMC10181943.
      Citations: 2     Fields:    Translation:HumansCells
    27. Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res. 2023 04 03; 29(7):1292-1304. PMID: 36595561; PMCID: PMC10290888.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    28. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604. PMID: 36928818; PMCID: PMC10033402.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    29. Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 02 13; 41(2):340-355.e6. PMID: 36787696; PMCID: PMC10259078.
      Citations: 10     Fields:    Translation:HumansCells
    30. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun. 2023 02 08; 14(1):695. PMID: 36755027; PMCID: PMC9908867.
      Citations: 4     Fields:    Translation:Humans
    31. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540. PMID: 36716413; PMCID: PMC9928880.
      Citations:    Fields:    Translation:Humans
    32. Kang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, Young I, Malin CM, Kang Y, Gibbons DL, Sica G, Fu H, Ramalingam SS, Jin L, Kang S. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Rep. 2022 Dec 13; 41(11):111827. PMID: 36516759.
      Citations:    Fields:    
    33. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117. PMID: 36371941.
      Citations:    Fields:    
    34. Bajaj R, Rodriguez BL, Russell WK, Warner AN, Diao L, Wang J, Raso MG, Lu W, Khan K, Solis LS, Batra H, Tang X, Fradette JF, Kundu ST, Gibbons DL. Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis. Cell Rep. 2022 09 27; 40(13):111429. PMID: 36170810; PMCID: PMC9665355.
      Citations:    Fields:    Translation:HumansCells
    35. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28. PMID: 35973335; PMCID: PMC10274087.
    36. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel). 2022 Jul 17; 14(14). PMID: 35884533; PMCID: PMC9323840.
    37. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6. PMID: 35820397; PMCID: PMC9667883.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    38. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, ICON Team. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2022 07; 6:e2200040. PMID: 35944232; PMCID: PMC9470146.
    39. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open. 2022 06 01; 5(6):e2215589. PMID: 35666500; PMCID: PMC9171557.
      Citations:    Fields:    Translation:Humans
    40. Rocha P, Zhang J, Laza-Briviesca R, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H, Cruz-Berm?dez A. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res. 2022 06 01; 28(11):2461-2473. PMID: 35394499; PMCID: PMC9167789.
      Citations:    Fields:    Translation:HumansCells
    41. Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harb Perspect Med. 2022 05 27; 12(5). PMID: 34580079; PMCID: PMC8957639.
      Citations: 1     Fields:    Translation:Humans
    42. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res. 2022 May 11; 41(1):172. PMID: 35546239; PMCID: PMC9092788.
      Citations:    Fields:    Translation:Humans
    43. Kundu ST, Rodriguez BL, Gibson LA, Warner AN, Perez MG, Bajaj R, Fradette JJ, Class CA, Solis LM, Rojas Alvarez FR, Wistuba II, Diao L, Chen F, Sachdeva M, Wang J, Kirsch DG, Creighton CJ, Gibbons DL. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev. 2022 05 01; 36(9-10):582-600. PMID: 35654454; PMCID: PMC9186390.
      Citations:    Fields:    Translation:AnimalsCells
    44. Bajaj R, Warner AN, Fradette JF, Gibbons DL. Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis. Cells. 2022 04 28; 11(9). PMID: 35563790; PMCID: PMC9102947.
      Citations:    Fields:    Translation:HumansCells
    45. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    46. Perez-Oquendo M, Gibbons DL. Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis. Cancers (Basel). 2022 Apr 07; 14(8). PMID: 35454770; PMCID: PMC9031734.
    47. Shah P, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C, Forget MA. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2). PMID: 35110355; PMCID: PMC8811607.
      Citations:    Fields:    Translation:HumansCells
    48. Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 05; 23(3):236-243. PMID: 35216923.
      Citations:    Fields:    Translation:Humans
    49. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337. PMID: 35190177; PMCID: PMC10228712.
      Citations:    Fields:    
    50. Rodriguez BL, Gibbons DL. MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression. Cell Rep Med. 2022 01 18; 3(1):100506. PMID: 35106515; PMCID: PMC8784763.
      Citations:    Fields:    Translation:HumansCells
    51. Deboever N, McGrail DJ, Lee Y, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Bernatchez C, Vailati Negrao M, Zhang J, Wistuba II, Heymach JV, Cascone T, Gibbons DL, Haymaker CL, Sepesi B. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75. PMID: 35038676.
      Citations:    Fields:    Translation:HumansCells
    52. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081. PMID: 34873156; PMCID: PMC8648877.
      Citations: 3     Fields:    Translation:HumansCells
    53. Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022 01 10; 40(1):36-52.e9. PMID: 34822775; PMCID: PMC8779329.
      Citations: 13     Fields:    Translation:HumansCells
    54. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655. PMID: 34789716; PMCID: PMC8599854.
      Citations: 3     Fields:    Translation:HumansCells
    55. Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, Bernatchez C, Heymach JV, Gibbons DL, Wang J, Xu L, Reuben A, Wang T. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell. 2021 Oct; 3(10):864-875. PMID: 36003885; PMCID: PMC9396750.
    56. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709. PMID: 34550757; PMCID: PMC8887948.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    57. Padhye A, Konen JM, Rodriguez BL, Fradette JJ, Ochieng JK, Diao L, Wang J, Lu W, Solis LS, Batra H, Raso MG, Peoples MD, Minelli R, Carugo A, Bristow CA, Gibbons DL. Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight. 2021 09 08; 6(17). PMID: 34309585; PMCID: PMC8492319.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    58. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045. PMID: 34413300; PMCID: PMC8376947.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    59. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5. PMID: 34377884; PMCID: PMC8345916.
      Citations: 5     Fields:    Translation:Humans
    60. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8). PMID: 34376553; PMCID: PMC8356172.
      Citations: 11     Fields:    Translation:Humans
    61. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021 11; 16(11):1821-1839. PMID: 34274504; PMCID: PMC8282443.
      Citations: 10     Fields:    Translation:HumansCells
    62. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1977-1978. PMID: 33686493; PMCID: PMC8195756.
      Citations:    Fields:    
    63. Tan X, Banerjee P, Shi L, Xiao GY, Rodriguez BL, Grzeskowiak CL, Liu X, Yu J, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. Sci Adv. 2021 06; 7(25). PMID: 34144984; PMCID: PMC8213221.
      Citations: 3     Fields:    Translation:AnimalsCells
    64. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discov. 2021 10; 11(10):2506-2523. PMID: 33972311; PMCID: PMC8487926.
      Citations: 12     Fields:    Translation:HumansCells
    65. Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606. PMID: 33972557; PMCID: PMC8110980.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    66. Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y, Tan X, Sheng K, Ahn YH, Lee S, Parra ER, Rodriguez-Canales J, Albritton J, Weiger M, Liu X, Guo HF, Yu J, Rodriguez BL, Firestone JJA, Mino B, Creighton CJ, Solis LM, Villalobos P, Raso MG, Sazer DW, Gibbons DL, Russell WK, Longmore GD, Wistuba II, Wang J, Chapman HA, Miller JS, Zong C, Kurie JM. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep. 2021 04 20; 35(3):109009. PMID: 33882319; PMCID: PMC8142261.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    67. Guo HF, Bota-Rabassedas N, Terajima M, Leticia Rodriguez B, Gibbons DL, Chen Y, Banerjee P, Tsai CL, Tan X, Liu X, Yu J, Tokmina-Roszyk M, Stawikowska R, Fields GB, Miller MD, Wang X, Lee J, Dalby KN, Creighton CJ, Phillips GN, Tainer JA, Yamauchi M, Kurie JM. A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. Commun Biol. 2021 04 19; 4(1):482. PMID: 33875777; PMCID: PMC8055892.
      Citations: 2     Translation:Animals
    68. Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021 07; 125(2):176-189. PMID: 33795809; PMCID: PMC8292398.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    69. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel). 2021 Mar 12; 13(6). PMID: 33809063; PMCID: PMC7998226.
      Citations: 3     
    70. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241; PMCID: PMC8818318.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    71. Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer. 2021 04; 154:76-83. PMID: 33631448.
      Citations: 5     Fields:    Translation:Humans
    72. Grigoryan B, Sazer DW, Avila A, Albritton JL, Padhye A, Ta AH, Greenfield PT, Gibbons DL, Miller JS. Development, characterization, and applications of multi-material stereolithography bioprinting. Sci Rep. 2021 02 04; 11(1):3171. PMID: 33542283; PMCID: PMC7862383.
      Citations: 14     Fields:    
    73. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. bioRxiv. 2021 Jan 28. PMID: 32577652; PMCID: PMC7302206.
    74. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021 Jul; 70(7):1965-1976. PMID: 33416944; PMCID: PMC8195808.
      Citations: 2     Fields:    Translation:Humans
    75. Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Res. 2021 03 01; 81(5):1398-1412. PMID: 33402388; PMCID: PMC8026531.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    76. Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J Clin Invest. 2021 01 04; 131(1). PMID: 32931483; PMCID: PMC7773359.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    77. Pradhan M, Gibbons DL, Sepesi B, Cascone T, Chocry M. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res. 2021 Jan; 10(1):590-606. PMID: 33569339; PMCID: PMC7867746.
      Citations: 9     
    78. Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. 2021 04; 16(4):601-609. PMID: 33388476; PMCID: PMC8012216.
      Citations: 10     Fields:    Translation:Humans
    79. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600. PMID: 33388477.
      Citations: 18     Fields:    Translation:Animals
    80. Monteiro de Oliveira Novaes JA, Hirz T, Guijarro I, Nilsson M, Pisegna MA, Poteete A, Barsoumian HB, Fradette JJ, Chen LN, Gibbons DL, Tian X, Wang J, Myers JN, McArthur MJ, Bell D, William WN, Heymach JV. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2021 03; 14(3):313-324. PMID: 33277316.
      Citations: 8     Fields:    Translation:Animals
    81. Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang B. KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475. PMID: 33415011; PMCID: PMC7783771.
      Citations: 7     
    82. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res. 2021 03; 19(3):485-497. PMID: 33172976; PMCID: PMC7925356.
      Citations: 9     Fields:    Translation:HumansCells
    83. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 11 04; 21(1):271. PMID: 33148332; PMCID: PMC7640699.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    84. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021 01; 16(1):127-139. PMID: 33096269; PMCID: PMC7775914.
      Citations: 10     Fields:    Translation:HumansCells
    85. Creelan BC, Yeh TC, Kim SW, Nogami N, Kim DW, Chow LQM, Kanda S, Taylor R, Tang W, Tang M, Angell HK, Roudier MP, Marotti M, Gibbons DL. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. Br J Cancer. 2021 01; 124(2):383-390. PMID: 33012782; PMCID: PMC7852511.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    86. Ochieng JK, Kundu ST, Bajaj R, Leticia Rodriguez B, Fradette JJ, Gibbons DL. MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs. Oncogene. 2020 10; 39(43):6719-6732. PMID: 32963352; PMCID: PMC7584762.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    87. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020 09 09; 11(1):4520. PMID: 32908154; PMCID: PMC7481212.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    88. Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020 09 02; 12(559). PMID: 32878980; PMCID: PMC8269000.
      Citations: 22     Fields:    Translation:HumansCells
    89. Bajaj R, Kundu ST, Grzeskowiak CL, Fradette JJ, Scott KL, Creighton CJ, Gibbons DL. IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. Oncogene. 2020 09; 39(37):5979-5994. PMID: 32753652; PMCID: PMC7539228.
      Citations: 11     Fields:    Translation:HumansCells
    90. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463. PMID: 32608142; PMCID: PMC7543335.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    91. Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer. 2020 08; 146:303-309. PMID: 32619781.
      Citations: 1     Fields:    Translation:Humans
    92. Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424. PMID: 32763065.
      Citations: 3     Fields:    Translation:Humans
    93. Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 2020 09; 91-92:8-18. PMID: 32442601.
      Citations: 14     Fields:    Translation:HumansCells
    94. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 39     Fields:    Translation:Humans
    95. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534. PMID: 32300858; PMCID: PMC7997043.
      Citations: 8     Fields:    Translation:HumansCells
    96. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer. 2020 04; 8(1). PMID: 32350118; PMCID: PMC7213906.
      Citations: 11     Fields:    Translation:HumansCells
    97. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536. PMID: 32193228; PMCID: PMC7446232.
      Citations: 7     Fields:    Translation:HumansCells
    98. Gaudreau PO, Lee JJ, Heymach JV, Gibbons DL. Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer. 2020 07; 21(4):384-388. PMID: 32299768; PMCID: PMC7656492.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    99. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol. 2020 05; 15(5):777-791. PMID: 32068166; PMCID: PMC7202130.
      Citations: 28     Fields:    Translation:Humans
    100. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603. PMID: 32001676; PMCID: PMC6992630.
      Citations: 54     Fields:    Translation:HumansCells
    101. Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM. PI4KIII? is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Sci Transl Med. 2020 01 22; 12(527). PMID: 31969487; PMCID: PMC7702266.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    102. Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells. 2019 12 24; 9(1). PMID: 31878283; PMCID: PMC7016859.
      Citations: 24     Fields:    Translation:HumansCells
    103. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    104. Manshouri R, Coyaud E, Kundu ST, Peng DH, Stratton SA, Alton K, Bajaj R, Fradette JJ, Minelli R, Peoples MD, Carugo A, Chen F, Bristow C, Kovacs JJ, Barton MC, Heffernan T, Creighton CJ, Raught B, Gibbons DL. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nat Commun. 2019 11 12; 10(1):5125. PMID: 31719531; PMCID: PMC6851102.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    105. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2020 02; 109(2):358-366. PMID: 31550464; PMCID: PMC7366360.
      Citations: 4     Fields:    Translation:Humans
    106. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625; PMCID: PMC6562947.
      Citations: 42     
    107. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565. PMID: 31067138; PMCID: PMC6599408.
      Citations: 229     Fields:    Translation:HumansCTClinical Trials
    108. Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel). 2019 Apr 02; 11(4). PMID: 30986992; PMCID: PMC6521201.
      Citations: 11     
    109. Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS, Gibbons DL. A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer. Sci Rep. 2019 03 20; 9(1):4819. PMID: 30894630; PMCID: PMC6427036.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    110. Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 03 13; 11(483). PMID: 30867319; PMCID: PMC6878763.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    111. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 2019 05; 9(5):646-661. PMID: 30777870; PMCID: PMC6563834.
      Citations: 202     Fields:    Translation:HumansAnimalsCells
    112. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031. PMID: 30780001.
      Citations: 35     Fields:    Translation:Humans
    113. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175. PMID: 30012853; PMCID: PMC6205194.
      Citations: 166     Fields:    Translation:HumansAnimalsCells
    114. Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, Chen K, Creighton CJ, Fu H, Mills GB, Gibbons DL, Scott KL. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. Nat Commun. 2018 07 16; 9(1):2732. PMID: 30013058; PMCID: PMC6048166.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    115. Kundu ST, Grzeskowiak CL, Fradette JJ, Gibson LA, Rodriguez LB, Creighton CJ, Scott KL, Gibbons DL. TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun. 2018 07 16; 9(1):2731. PMID: 30013069; PMCID: PMC6048095.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    116. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 07 02; 128(7):3198. PMID: 30108197; PMCID: PMC6025981.
      Citations: 12     Fields:    
    117. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II, Forget MA. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48. PMID: 29871672; PMCID: PMC5989476.
      Citations: 60     Fields:    Translation:Humans
    118. Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791. PMID: 29526824.
      Citations: 30     Fields:    Translation:Humans
    119. Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1621-1626. PMID: 29510096.
      Citations: 4     Fields:    Translation:Humans
    120. Tan X, Banerjee P, Liu X, Yu J, Gibbons DL, Wu P, Scott KL, Diao L, Zheng X, Wang J, Jalali A, Suraokar M, Fujimoto J, Behrens C, Liu X, Liu CG, Creighton CJ, Wistuba II, Kurie JM. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282. PMID: 29324442; PMCID: PMC5873879.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    121. Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ. Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res. 2018 05 01; 24(9):2182-2193. PMID: 29440175; PMCID: PMC5932236.
      Citations: 34     Fields:    Translation:HumansCells
    122. Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The fibrotic tumor stroma. J Clin Invest. 2018 01 02; 128(1):16-25. PMID: 29293090; PMCID: PMC5749516.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    123. Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 2017; 7(1):e1376156. PMID: 29296537; PMCID: PMC5739569.
      Citations: 8     Fields:    
    124. Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J, Forget MA. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017 10 17; 7(1):13380. PMID: 29042640; PMCID: PMC5645415.
      Citations: 89     Fields:    Translation:Humans
    125. Wei Y, Kim TJ, Peng DH, Duan D, Gibbons DL, Yamauchi M, Jackson JR, Le Saux CJ, Calhoun C, Peters J, Derynck R, Backes BJ, Chapman HA. Fibroblast-specific inhibition of TGF-?1 signaling attenuates lung and tumor fibrosis. J Clin Invest. 2017 Oct 02; 127(10):3675-3688. PMID: 28872461; PMCID: PMC5617667.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    126. Chen F, Zhang Y, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ, Boss? D. Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun. 2017 08 04; 8(1):199. PMID: 28775315; PMCID: PMC5543131.
      Citations: 28     Fields:    Translation:HumansCells
    127. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J, Forget MA. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097. PMID: 28733428; PMCID: PMC5628137.
      Citations: 67     Fields:    Translation:Humans
    128. Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017 07 15; 77(14):3870-3884. PMID: 28490518; PMCID: PMC5563854.
      Citations: 75     Fields:    Translation:HumansAnimalsCells
    129. Gibbons DL, Creighton CJ. Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. Dev Dyn. 2018 03; 247(3):555-564. PMID: 28073171; PMCID: PMC5503821.
      Citations: 40     Fields:    Translation:HumansCells
    130. Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017 Apr 25; 8(17):28575-28587. PMID: 28212573; PMCID: PMC5438673.
      Citations: 71     Fields:    Translation:HumansCells
    131. Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res. 2017 04; 5(4):319-329. PMID: 28254787; PMCID: PMC5673248.
      Citations: 6     Fields:    Translation:HumansCells
    132. Tan X, Banerjee P, Guo HF, Ireland S, Pankova D, Ahn YH, Nikolaidis IM, Liu X, Zhao Y, Xue Y, Burns AR, Roybal J, Gibbons DL, Zal T, Creighton CJ, Ungar D, Wang Y, Kurie JM. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. J Clin Invest. 2017 01 03; 127(1):117-131. PMID: 27869652; PMCID: PMC5199715.
      Citations: 39     Fields:    Translation:HumansCells
    133. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE, Forget MA. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168. PMID: 27776519; PMCID: PMC5078889.
      Citations: 64     Fields:    Translation:HumansCells
    134. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196; PMCID: PMC5143183.
      Citations: 308     Fields:    Translation:HumansCTClinical Trials
    135. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147; PMCID: PMC5065110.
      Citations: 67     Fields:    
    136. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology. 2016; 5(11):e1234570. PMID: 27999749; PMCID: PMC5139626.
      Citations: 13     Fields:    
    137. Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y. A genetic cell context-dependent role for ZEB1 in lung cancer. Nat Commun. 2016 07 26; 7:12231. PMID: 27456471; PMCID: PMC4963474.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    138. Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y. Musashi-2 (MSI2) supports TGF-? signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016 06 21; 113(25):6955-60. PMID: 27274057; PMCID: PMC4922167.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    139. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289. PMID: 27252415; PMCID: PMC5558040.
      Citations: 63     Fields:    Translation:HumansCells
    140. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42. PMID: 26851185; PMCID: PMC4947453.
      Citations: 206     Fields:    Translation:HumansCells
    141. Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, Gibbons DL. The microRNA-200/Zeb1 axis regulates ECM-dependent ?1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep. 2016 Jan 05; 6:18652. PMID: 26728244; PMCID: PMC4700473.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    142. Albritton JL, Roybal JD, Paulsen SJ, Calafat N, Flores-Zaher JA, Farach-Carson MC, Gibbons DL, Miller JS. Ultrahigh-throughput Generation and Characterization of Cellular Aggregates in Laser-ablated Microwells of Poly(dimethylsiloxane). RSC Adv. 2016 Jan 01; 6(11):8980-8991. PMID: 26998251; PMCID: PMC4792302.
      Citations: 13     
    143. Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, Sun L, Gill BJ, Vadakkan TJ, Kim MP, Ahn YH, Roybal JD, Liu X, Parra Cuentas ER, Rodriguez J, Wistuba II, Creighton CJ, Gibbons DL, Hicks JM, Dickinson ME, West JL, Grande-Allen KJ, Hanash SM, Yamauchi M, Kurie JM. Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2016 Mar; 14(3):287-95. PMID: 26631572; PMCID: PMC4794404.
      Citations: 67     Fields:    Translation:AnimalsCells
    144. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1674-1686. PMID: 26597303; PMCID: PMC4818738.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    145. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20. PMID: 26420858; PMCID: PMC4737991.
      Citations: 203     Fields:    Translation:HumansCells
    146. Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology. 2015 May; 4(5):e1002731. PMID: 26155392; PMCID: PMC4485725.
      Citations: 18     Fields:    
    147. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241. PMID: 25348003; PMCID: PMC4212319.
      Citations: 409     Fields:    Translation:HumansAnimalsCells
    148. Gibbons DL, Byers LA. A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow. Cancer Discov. 2014 Sep; 4(9):991-4. PMID: 25185188; PMCID: PMC4990388.
      Citations: 5     Fields:    Translation:Humans
    149. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708. PMID: 24762440; PMCID: PMC4038569.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    150. Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quint?s-Cardama A. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014 Mar 04; 111(9):3550-5. PMID: 24550512; PMCID: PMC3948238.
      Citations: 32     Fields:    Translation:HumansCells
    151. Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014 Jan; 12(1):3-13. PMID: 24442106; PMCID: PMC3925633.
      Citations: 98     Fields:    Translation:HumansAnimals
    152. Mishra DK, Creighton CJ, Zhang Y, Gibbons DL, Kurie JM, Kim MP. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer. 2014 Feb 15; 134(4):789-98. PMID: 23934967; PMCID: PMC4070715.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    153. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res. 2013; 5:187-95. PMID: 23986650; PMCID: PMC3754282.
      Citations: 67     
    154. Laurini E, Posocco P, Fermeglia M, Gibbons DL, Pricl S, Quint?s-Cardama A. Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. Mol Oncol. 2013 Oct; 7(5):968-75. PMID: 23816609; PMCID: PMC5528448.
      Citations: 10     Fields:    Translation:HumansCells
    155. Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013; 8(6):e67054. PMID: 23785517; PMCID: PMC3677922.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    156. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013 Aug; 3(8):870-9. PMID: 23715154; PMCID: PMC3753578.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    157. Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, West JL. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012 Nov 15; 72(22):6013-23. PMID: 22952217; PMCID: PMC3632398.
      Citations: 68     Fields:    Translation:AnimalsCells
    158. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012 Sep; 122(9):3170-83. PMID: 22850877; PMCID: PMC3428095.
      Citations: 96     Fields:    Translation:HumansAnimalsCells
    159. Chatterjee S, Seifried L, Feigin ME, Gibbons DL, Scuoppo C, Lin W, Rizvi ZH, Lind E, Dissanayake D, Kurie J, Ohashi P, Muthuswamy SK. Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells. PLoS One. 2012; 7(4):e34343. PMID: 22529912; PMCID: PMC3329530.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    160. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH, Kurie JM, Hanash SM. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011 Dec 15; 71(24):7670-82. PMID: 21987723; PMCID: PMC3419137.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    161. Ahn YH, Yang Y, Gibbons DL, Creighton CJ, Yang F, Wistuba II, Lin W, Thilaganathan N, Alvarez CA, Roybal J, Goldsmith EJ, Tournier C, Kurie JM. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol. 2011 Nov; 31(21):4270-85. PMID: 21896780; PMCID: PMC3209326.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    162. Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quint?s-Cardama A. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9. PMID: 21732333; PMCID: PMC6896214.
      Citations: 24     Fields:    Translation:Humans
    163. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011 Apr; 121(4):1373-85. PMID: 21403400; PMCID: PMC3069760.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    164. Cataldo VD, Gibbons DL, P?rez-Soler R, Quint?s-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011 Mar 10; 364(10):947-55. PMID: 21388312.
      Citations: 143     Fields:    Translation:HumansCells
    165. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011 Jan; 9(1):25-35. PMID: 21115742; PMCID: PMC3232024.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    166. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009 Sep 15; 23(18):2140-51. PMID: 19759262; PMCID: PMC2751985.
      Citations: 250     Fields:    Translation:AnimalsCells
    167. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401. PMID: 19404390; PMCID: PMC2671160.
      Citations: 42     Fields:    Translation:Animals
    168. Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. J Biol Chem. 2009 Jun 26; 284(26):17766-74. PMID: 19398556; PMCID: PMC2719415.
      Citations: 27     Fields:    Translation:HumansCells
    169. Gibbons DL, Quint?s-Cardama A. Five-gene signature in non-small-cell lung cancer. N Engl J Med. 2007 Apr 12; 356(15):1582-3; author reply 1583. PMID: 17436429.
      Citations:    Fields:    Translation:HumansCells
    170. Gibbons DL, Erk I, Reilly B, Navaza J, Kielian M, Lepault J, Rey FA. Visualization of the target-membrane-inserted fusion protein of Semliki Forest virus by combined electron microscopy and crystallography. Cell. 2003 Sep 05; 114(5):573-83. PMID: 13678581.
      Citations: 63     Fields:    Translation:AnimalsCells
    171. Sweadner KJ, Herrera VL, Amato S, Moellmann A, Gibbons DK, Repke KR. Immunologic identification of Na+,K(+)-ATPase isoforms in myocardium. Isoform change in deoxycorticosterone acetate-salt hypertension. Circ Res. 1994 Apr; 74(4):669-78. PMID: 8137503.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    172. The mutually regulatory loop of epithelial- mesenchymal transition and immunosuppression in cancer progression. OncoImmunology. 4.
    173. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. Journal of Clinical Investigation. 127:117-131.
    174. The role of MicroRNAs in lung cancer development, progression, and metastasis. 73-89.
    175. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research. 22:3630-3642.
    176. The authors reply. New England Journal of Medicine. 364:2368.
    177. Ultrahigh-throughput generation and characterization of cellular aggregates in laser-ablated microwells of poly(dimethylsiloxane). RSC Advances. 6:8980-8991.
    178. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clinical Cancer Research. 22:6278-6289.
    179. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. International Journal of Cancer. 134:789-798.
    180. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America. 113:6955-6960.
    181. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. 22:609-620.
    182. Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Molecular Cancer Research. 14:287-295.
    183. A genetic cell context-dependent role for ZEB1 in lung cancer. Nature Communications. 7.
    184. A HER 1-2 Punch. Cancer Discovery. 4:991-994.
    185. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clinical Cancer Research. 22:1674-1686.
    186. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene.
    187. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    188. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. OncoImmunology.
    189. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Scientific Reports. 6.
    190. The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene.
    191. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.
    192. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    GIBBONS's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (501)
    Co-Authors (178)
    Similar People (60)
    Same Department Expand Description